The challenge of rational development of complex natural products as cancer therapeutics

Journal of the National Cancer Institute

Volumn 102, Issue 12, 2010, Pages 834-835

  White, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AE 941; GREEN TEA EXTRACT; HERBACEOUS AGENT; NATURAL PRODUCT; PLANT EXTRACT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; SHARK CARTILAGE EXTRACT; TISSUE EXTRACT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CONDYLOMA ACUMINATUM; CYTOTOXICITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TEA; ADJUVANT CHEMOTHERAPY; CARTILAGE; HUMAN; LUNG TUMOR; NATIONAL HEALTH ORGANIZATION; NEOPLASM; NOTE; RANDOMIZED CONTROLLED TRIAL; STANDARD; UNITED STATES;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL PRODUCTS; CARCINOMA, NON-SMALL-CELL LUNG; CARTILAGE; CHEMOTHERAPY, ADJUVANT; HUMANS; LUNG NEOPLASMS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE EXTRACTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77953717769     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq196     Document Type: Editorial

References (16)

1. Lu C, Lee JJ, Komaki R, et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst. 2010; 102 (12): 859-865.
2. Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group Trial. Cancer. 2005; 104 (1): 176-182.
3. Oh WK, Kantoff PW, Weinberg V, et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstil-bestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004; 22 (18): 3705-3712.
4. Diamond WJ, Cowden WL, Goldberg B. An Alternative Medicine Defi nitive Guide to Cancer. Tiburon, CA: Future Medicine Publishing, Inc.; 1997.
5. Habermann TM, Thompson CA, LaPlant BR, et al. Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. Am J Hematol. 2009; 84 (12): 795-798.
6. Hyodo I, Amano N, Eguchi K, et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol. 2005; 23 (12): 2645-2654.
7. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000; 18 (13): 2505-2514.
8. FDA Drug Approval Package: Veregen Ointment; Company: MediGene, Inc. Application No.: 021902; Approval Date: 10/31/2006. http://www.accessdata.fda. gov/drugsatfda-docs/nda/2006/021902s000TOC.cfm. Accessed April 26,2010.
9. Dupont E, Falardeau P, Mousa SA, et al. Antiangiogenic and antimeta-static properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis. 2002; 19 (2): 145-153.
10. Hassan ZM, Feyzi R, Sheikhian A, et al. Low molecular weight fraction of shark cartilage can modulate immune responses and abolish angiogenesis. Int Immunopharmacol. 2005; 5 (6): 961-970.
11. Horsman MR, Alsner J, Overgaard J. The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. Acta Oncol. 1998; 37 (5): 441-445.
12. Berbari P, Thibodeau A, Germain L, et al. Antiangiogenic effects of the oral administration of liquid cartilage extract in humans. J Surg Res. 1999; 87 (1): 108-113.
13. Latreille J, Batist G, Laberge F, et al. Phase I/II trial of the safety and effi cacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003; 4 (4): 231-236.
14. Miller DR, Anderson GT, Stark JJ. Granick, JL, Richardson D. Phase I/II trial of the safety and effi cacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998; 16: 3649-3655.
15. Kern BE, Balcom JH, Antoniu BA, Warshaw AL. Fernandez-del Castillo C. Troponin I peptide (Glu94-Leu123), a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer. J Gastrointest Surg. 2003; 7 (8): 961-968; discussion 69.
16. Zheng L, Ling P, Wang Z, et al. A novel polypeptide from shark cartilage with potent anti-angiogenic activity. Cancer Biol Ther. 2007; 6 (5): 775-780.